Fady Ibraham Malik Cytokinetics Inc (CYTK) insider trading activity

Fady Ibraham Malik is EVP Research & Development of CYTOKINETICS INC. Currently has a direct ownership of 116,071 shares of CYTK, which is worth approximately $5.5 Million. The most recent transaction as insider was on Jul 09, 2024, when has been sold 5,300 shares (Common Stock) at a price of $7.96 per share, resulting in proceeds of $42,188. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 116K

4.01% 3M change

22.96% 12M change

Total Value Held $5.5 Million

Fady Ibraham Malik Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 09 2024	BUY Exercise of conversion of derivative security	$42,188 $7.96 p/Share	5,300 Added 3.69%	138,304 Common Stock
Jun 25 2024	SELL Open market or private sale	$392,229 $53.73 p/Share	7,300 Reduced 5.2%	133,004 Common Stock
Jun 25 2024	BUY Exercise of conversion of derivative security	$42,188 $7.96 p/Share	5,300 Added 3.69%	138,304 Common Stock
Jun 11 2024	SELL Open market or private sale	$413,075 $53.04 p/Share	7,788 Reduced 5.45%	135,004 Common Stock
Jun 11 2024	BUY Exercise of conversion of derivative security	$43,159 $7.96 p/Share	5,422 Added 3.66%	142,792 Common Stock
May 07 2024	SELL Open market or private sale	$1,012,265 $65.11 p/Share	15,547 Reduced 10.19%	137,056 Common Stock
May 07 2024	BUY Exercise of conversion of derivative security	$94,620 $6.67 p/Share	14,186 Added 8.51%	152,603 Common Stock
Apr 12 2024	SELL Bona fide gift	-	150 Reduced 0.11%	138,417 Common Stock
Apr 09 2024	SELL Open market or private sale	$2,422,877 $74.31 p/Share	32,605 Reduced 19.05%	138,567 Common Stock
Apr 09 2024	BUY Exercise of conversion of derivative security	$190,795 $6.67 p/Share	28,605 Added 14.32%	171,172 Common Stock
Mar 14 2024	BUY Grant, award, or other acquisition	-	21,333 Added 13.02%	142,567 Common Stock
Mar 06 2024	SELL Payment of exercise price or tax liability	$542,329 $66.88 p/Share	8,109 Reduced 6.27%	121,234 Common Stock
Mar 05 2024	SELL Open market or private sale	$2,202,074 $67.54 p/Share	32,604 Reduced 19.0%	138,973 Common Stock
Mar 05 2024	BUY Exercise of conversion of derivative security	$190,788 $6.67 p/Share	28,604 Added 14.58%	167,577 Common Stock
Mar 04 2024	SELL Payment of exercise price or tax liability	$651,758 $67.68 p/Share	9,630 Reduced 6.74%	133,343 Common Stock
Feb 06 2024	SELL Open market or private sale	$2,585,250 $79.29 p/Share	32,605 Reduced 18.57%	142,973 Common Stock
Feb 06 2024	BUY Exercise of conversion of derivative security	$190,795 $6.67 p/Share	28,605 Added 14.01%	175,578 Common Stock
Jan 04 2024	SELL Open market or private sale	$1,363,829 $86.99 p/Share	15,678 Reduced 9.64%	146,973 Common Stock
Jan 04 2024	BUY Exercise of conversion of derivative security	$92,956 $7.96 p/Share	11,678 Added 6.7%	162,651 Common Stock
Nov 09 2023	SELL Open market or private sale	$88,500 $35.4 p/Share	2,500 Reduced 1.63%	150,664 Common Stock
Oct 12 2023	SELL Open market or private sale	$89,725 $35.89 p/Share	2,500 Reduced 1.61%	153,164 Common Stock
Sep 14 2023	SELL Open market or private sale	$87,150 $34.86 p/Share	2,500 Reduced 1.58%	155,664 Common Stock
Aug 10 2023	SELL Open market or private sale	$79,250 $31.7 p/Share	2,500 Reduced 1.56%	158,164 Common Stock
Jul 13 2023	SELL Open market or private sale	$88,425 $35.37 p/Share	2,500 Reduced 1.53%	160,664 Common Stock
Jun 08 2023	SELL Open market or private sale	$95,175 $38.07 p/Share	2,500 Reduced 1.51%	163,164 Common Stock

Also insider at

RCKT

ROCKET PHARMACEUTICALS, INC. Healthcare

FIM